Frontiers | MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance Immunotherapies have transformed cancer treatment by harnessing the immune system to recognize and eliminate malignant cells, offering durable clinical benef...

New review just out in Frontiers in Immunology! 🎉

We dive into how #MYC reshapes the tumor–immune interface to drive #immuneescape and resistance to #immunotherapy.
Open access here 👉 www.frontiersin.org/journals/imm...
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc

2026-002-01 Research Laboratory Technician / Lab Manager - VHIO Under the leadership of Josep Tabernero, VHIO is an internationally recognized cancer center. Its multidisciplinary, collaborative model drives scientific progress and innovative cancer treatments.

We are hiring! If you are interested in joining our Models of Cancer Therapy Laboratory lab at @vhio.bsky.social as a Research Laboratory Technician / Lab Manager, apply here: jobs.vhio.net/en/jobs/7018...

Frontiers | The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition MYC performs a dual role in DNA Damage Response (DDR), promoting genomic instability through replication stress, R-loop formation, and topoisomerase-mediated...

Really happy to share our new open-access review in Frontiers in Cell and Developmental Biology 🎉
#MYC inhibition creates vulnerabilities that can be targeted with #DDR inhibitors.
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc @lsouceklab.bsky.social
www.frontiersin.org/journals/cel...

Honored to deliver a keynote today at the 19th Scientific Day & 29th Annual Conference of Vall d’Hebron on collaborative, challenge-driven research with transformative health impact. #MYC #OMO-103 #Omomyc
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer Giuntini et al. demonstrate that Omomyc, the only direct MYC inhibitor currently in phase 2 clinical trials, causes DNA damage and synergizes with PARPis in triple-negative breast cancer. Their findin...

Link to the article: www.cell.com/cell-reports...

Huge thanks to Fabio Giuntini, and to the entire teams at
@vhio.bsky.social and #peptomyc for making this possible. We also want to acknowledge the support of
#AECMM and the @erc.europa.eu for backing research that can make a real difference.

In triple-negative breast cancer (TNBC), #Omomyc/#OMO-103 shuts down DNA-repair gene programs, triggers DNA damage and — in combination with PARP inhibitors — restores response even in PARPi-resistant models.

Our work MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer has been accepted in
@cp-cellreports.bsky.social : 🚀

Our news of the week: Poster presented at the first annual @sosclc-aecc.bsky.social Symposium, showcasing the work of Ana Lopez Garza and Hugo Thabussot on #SCLC research, conducted as part of the #AECC 70% Survivorship Challenge. @vhio.bsky.social #peptomyc

Thrilled to share that our senior PhD student Íñigo Gonzalez has presented a poster on MYC inhibition and re-activation of tumor immunity in KRAS-driven NSCLC with diverse mutational profiles in @CellSymposia Cancer-Immunity Cycle. #ImmunoOncology #CancerTreatment #CSCancerImmunity2025

Honored to present our MYC inhibitor research at the Cancer–Immunity Cycle @CellSymposia and connect with leaders in immuno-oncology. Presented by Silvia Casacuberta 👏
#CancerResearch #ImmunoOncology #CancerTreatment #CSCancerImmunity2025

Being normal is overrated. Happy Halloween from the LSoucek lab!

Proud to see our Íñigo González Larreategui presenting a flash talk and poster at #aseicacongress in Bilbao on the therapeutic impact and reactivation of tumor immunity by MYC inhibition in KRAS-driven NSCLC with diverse mutational landscapes. 👏 @aseica.bsky.social

Intense week for @LSoucekLab! We are happy to see our @dcapi14 presenting a poster on Targeting oncogene cooperation: MYC inhibition enhances response and overcomes resistance to KRAS inhibitors. #TargetingRAS2025 @TargetingRAS Targeting RAS symposium, Salamanca, 2025 👏💪

MYC in cancer: from undruggable target to clinical trials Nature Reviews Drug Discovery - Oncogene MYC has been considered ‘undruggable’ for many decades. This Review provides an overview of the various strategies to inhibit MYC, focusing on...

We are delighted to share that the review “MYC in cancer: from undruggable target to clinical trials” by Jonathan Whitfield and @lsoucek.bsky.social is finally out in Nature Review Drug Discovery. What an amazing journey this has been and still promises to be!
rdcu.be/eawOK

@lsoucek.bsky.social is presenting today a seminar at UB regarding the challenge associated to the development of a MYC inhibitor. Info below.